Tetraphase Pharma (TTPH) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tetraphase Pharmaceuticals Reports Second-Quarter 2015 Financial Results
August 5, 2015 4:01 PM EDTWATERTOWN, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended June 30, 2015.
"We made significant progress against our 2015 objectives in the second quarter," said Guy Macdonald, Tetraphase's President and Chief Executive Officer. "We reported detailed positive results from IGNITE1, the Company's pivotal phase 3 clinical trial evaluating the... More
Tetraphase Pharmaceuticals Reports Second-Quarter 2015 Financial Results
August 5, 2015 4:01 PM EDTWATERTOWN, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the quarter ended June 30, 2015.
"We made significant progress against our 2015 objectives in the second quarter," said Guy Macdonald, Tetraphase's President and Chief Executive Officer. "We reported detailed positive results from IGNITE1, the Company's pivotal phase 3 clinical trial evaluating the... More
